AGAndrei Gurau

Andrei Gurau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrei Gurau has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A neurocutaneous Na V 1.8 channelopathy underlies a genetic subtype of primary idiopathic hyperhidrosis

    by Suguru Yamauchi, Jolien Vander Cruyssen, Michele Cervellera, Elizabeth Wohler, Jolien De Waele, Maxime Lammens, Corinne Boehm, Nara L Sobreira, Carley Blevins, Kaitlyn Ecoff, et al.

    Primary idiopathic hyperhidrosis (PIH) is a poorly understood disorder characterized by excessive sweating. We identify a genetically defined subset of PIH associated with rare coding changes in voltage-gated Na + (Na V ) channels. Whole-exome sequencing of hereditary PIH families revealed gene-level enrichment within the Na V channel family, with SCN10A (Na V 1.8) most strongly implicated. A knock-in mouse carrying the clinically observed Na V 1.8 p.R14L substitution recapitulated excessive sweating. Na V 1.8 was detected in a subset of postganglionic neurons in thoracic sympathetic ganglia in humans and mice, where p.R14L produced a gain-of-function profile that enhanced cholinergic responsiveness. Excessive sweating in mutant mice was reversible with Na V channel inhibition, including clinically used agents and a Na V 1.8-preferential compound. Together, these findings define a targetable neurocutaneous channelopathy underlying a subset of PIH and support a model in which excessive sweating arises from either gland-intrinsic dysfunction or altered sympathetic drive, motivating stratified therapeutic approaches.

  • Open Access

    Supplemental Table 3 from Epigenetic Instability–Based Metrics in Cell-Free DNA for Early Cancer Detection

    by Sara-Jayne Thursby, Zhicheng Jin, Jacob Blum, Andrei Gurau, Michaël Noë, Robert B. Scharpf, Victor E. Velculescu, Leslie Cope, Malcolm Brock, Stephen Baylin, et al.

  • Open Access

    Supplemental Table 1 from Epigenetic Instability–Based Metrics in Cell-Free DNA for Early Cancer Detection

    by Sara-Jayne Thursby, Zhicheng Jin, Jacob Blum, Andrei Gurau, Michaël Noë, Robert B. Scharpf, Victor E. Velculescu, Leslie Cope, Malcolm Brock, Stephen Baylin, et al.

  • Open Access

    Supplemental Table 2 from Epigenetic Instability–Based Metrics in Cell-Free DNA for Early Cancer Detection

    by Sara-Jayne Thursby, Zhicheng Jin, Jacob Blum, Andrei Gurau, Michaël Noë, Robert B. Scharpf, Victor E. Velculescu, Leslie Cope, Malcolm Brock, Stephen Baylin, et al.

  • Open Access

    Supplementary Data 1 from Epigenetic Instability–Based Metrics in Cell-Free DNA for Early Cancer Detection

    by Sara-Jayne Thursby, Zhicheng Jin, Jacob Blum, Andrei Gurau, Michaël Noë, Robert B. Scharpf, Victor E. Velculescu, Leslie Cope, Malcolm Brock, Stephen Baylin, et al.

  • Open Access

    Data from Epigenetic Instability–Based Metrics in Cell-Free DNA for Early Cancer Detection

    by Sara-Jayne Thursby, Zhicheng Jin, Jacob Blum, Andrei Gurau, Michaël Noë, Robert B. Scharpf, Victor E. Velculescu, Leslie Cope, Malcolm Brock, Stephen Baylin, et al.

    Purpose:Cancers present significant DNA methylation changes, which arise in a stochastic manner, marked by extensive epigenetic variation, indicative of high epigenetic instability. We aimed to evaluate the utility of epigenetic instability for cell-free DNA (cfDNA)-based cancer detection.Experimental Design:Through analysis of cancer DNA methylation datasets (n = 2,084), we identified a set of 269 CpG island regions that robustly captures this instability in a cancer-specific manner. We developed metrics to measure this epigenetic instability, termed the epigenetic instability index (EII), for cancer screening via cfDNA methylation.Results:Machine learning classifiers using the EII of these 269 regions efficiently identified breast and lung cancers from cfDNA, differentiating even stage IA lung adenocarcinoma with ∼81% sensitivity and early-stage breast cancer with ∼68% sensitivity, both at 95% specificity.Conclusions:Our studies demonstrate that quantifying epigenetic instability is a novel, capable approach to distinguishing cancer from normal cases using cfDNA, performing better than standard approaches using absolute methylation changes. The epigenetic instability–based approaches for cancer detection developed here, along with their validation in independent datasets, support further development and the potential for future clinical application of these strategies in cancer screening.

  • Open Access

    Epigenetic Instability–Based Metrics in Cell-Free DNA for Early Cancer Detection

    by Sara-Jayne Thursby, Zhicheng Jin, Jacob Blum, Andrei Gurau, Michaël Noë, Robert B. Scharpf, Victor E. Velculescu, Leslie Cope, Malcolm Brock, Stephen Baylin, et al.

    Purpose: Cancers present significant DNA methylation changes, which arise in a stochastic manner, marked by extensive epigenetic variation, indicative of high epigenetic instability. We aimed to evaluate the utility of epigenetic instability for cell-free DNA (cfDNA)-based cancer detection. Experimental Design: Through analysis of cancer DNA methylation datasets (n = 2,084), we identified a set of 269 CpG island regions that robustly captures this instability in a cancer-specific manner. We developed metrics to measure this epigenetic instability, termed the epigenetic instability index (EII), for cancer screening via cfDNA methylation. Results: Machine learning classifiers using the EII of these 269 regions efficiently identified breast and lung cancers from cfDNA, differentiating even stage IA lung adenocarcinoma with ∼81% sensitivity and early-stage breast cancer with ∼68% sensitivity, both at 95% specificity. Conclusions: Our studies demonstrate that quantifying epigenetic instability is a novel, capable approach to distinguishing cancer from normal cases using cfDNA, performing better than standard approaches using absolute methylation changes. The epigenetic instability–based approaches for cancer detection developed here, along with their validation in independent datasets, support further development and the potential for future clinical application of these strategies in cancer screening.


  • Primary focal hyperhidrosis and autonomic symptom burden: a case–control study using the COMPASS-31 questionnaire

    by Andrei Gurau, Wasay Nizam, Hamza Khan, Nimisha Seshadri, Christine Kim, Suguru Yamauchi, Rita de Cássia Collaço, Ruilin Ma, Kaitlyn Ecoff, Jolien Vander Cruyssen, et al.

    Purpose To explore the relationship between primary focal hyperhidrosis (PFH) and generalized autonomic dysfunction, we assessed autonomic symptom burden using a comprehensive and validated measure of autonomic symptoms. Methods In this case–control study, we compared 132 patients with PFH with 74 matched healthy controls. Autonomic symptoms were assessed using the Composite Autonomic Symptom Score-31 (COMPASS-31) questionnaire. Propensity score matching minimized confounding. Mann–Whitney U tests compared COMPASS-31 scores between groups. A sensitivity analysis using multivariate linear regression accounted for specific hyperhidrosis sites and demographic factors. Results PFH cases demonstrated significantly higher median COMPASS-31 scores compared to controls (18.7 [IQR 7.7–34.8] vs. 11.2 [IQR 3.5–19.3], p < 0.001). Significant differences were observed in orthostatic (2.0 [0–20] vs. 0 [0–12], p = 0.028), vasomotor (0 [0–0] vs. 0 [0–0], p = 0.005; 24.2% vs. 9.5% non-zero scores, respectively), secretomotor (3.2 [2.1–8.6] vs. 0 [0–3.8], p < 0.001), and gastrointestinal (5.4 [1.8–8] vs. 1.8 [0.9–5.4], p = 0.004) domains. Sensitivity analysis confirmed PFH status as a significant predictor of higher COMPASS-31 scores (additional 7.5 points on average, 95% CI 1.6–13.4, p = 0.012) after adjusting for demographic factors and hyperhidrosis sites. Craniofacial and truncal hyperhidrosis were associated with higher autonomic symptom burden. Conclusion PFH is associated with a broader spectrum of autonomic symptoms beyond localized sweating, establishing a link to more generalized autonomic dysfunction. These findings underscore the need for a comprehensive approach to evaluating and managing patients with PFH.


  • Open Access

    PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy

    by Andrei Gurau, Suguru Yamauchi, Kaitlyn Ecoff, Kristen P. Rodgers, James R. Eshleman, Charles Conover Talbot Jr, Peng Huang, Joshua Choi, Patrick M. Forde, Valsamo Anagnostou, et al.

    A new therapeutic avenue combining Durvalumab with cisplatin-pemetrexed (Durva-CP) has delivered a promising outcome for previously untreated patients with unresectable malignant pleural mesothelioma (MPM) in clinical trials. However, the limited patient response to Durva-CP needs predictors to select optimal candidates and monitor the developed resistance. Protein functional effector sncRNA (pfeRNA) reveals a fundamental mechanism underlying the regulation of protein activity. The common mechanisms underlying durvalumab, cisplatin, and pemetrexed indicate that PD-L1 pfeRNAs (PDLpfeRNAs) are key molecules that control the treatment response. We specified PDLpfeRNAs by sncRNA deep sequencing, confirmed their binding to PD-L1 by immunoprecipitation and reverse pull-down assays, and demonstrated their roles in controlling the interaction behaviors of PD1/L1 through quality-controlled drug development assays. Following the standards required for the CLIA-compliant LDT, we measured their expression levels in 60 plasma biospecimens from 30 unresectable MPM patients enrolled in the PrE0505 Phase II multicenter study. Using the Cox proportional hazards model and Kaplan-Meier analyses, we described their significance in predicting the treatment response of unresectable MPM patients administered Durva-CP as first-line therapy. Two PDLpfeRNAs, PDLpfeRNAa and PDLpfeRNAb, were characterized, confirmed to bind to PD-L1, and identified to control the interaction behaviors of PD-1/L1. Their plasma relative expression levels (REL) demonstrated significant prognostic value for both overall survival (p = 0.0019) and progression-free survival (p = 0.019), and the association remained significant after adjusting for histological subtype (HR 2.59, 95 % CI: 1.00-6.70, p = 0.050) and age (HR 1.03, 95 % CI: 0.98-1.07, p = 0.269). Plasma PDLpfeRNAs are predictors of treatment response of unresectable MPM patients treated with Durva-CP as first-line therapy to select optimal candidates and monitor the developed resistance.


  • Racial Disparities in the Use of Minimally Invasive Surgery for Gastrointestinal Cancer

    by Andrei Gurau, Olivia Monton, Jonathan B. Greer, Norman G. Nicolson, Fabian M. Johnston

    Introduction: Racial disparities in minimally invasive surgery (MIS) utilization across gastrointestinal (GI) cancers are not well characterized. We evaluated racial/ethnic disparities in the use of MIS approaches and associated outcomes. Methods: We analyzed a cohort of patients with GI cancer in the National Cancer Database (2010–2020). Multinomial logistic regression was used to evaluate associations between race/ethnicity and approach. Logistic regression was used to assess 30‐day readmission and 90‐day mortality. Cox regression was used to analyze overall survival. Models were adjusted for demographics, clinical characteristics, cancer factors, and facility features. Results: Of the 839 398 patients included, 76.9% were White, 11.6% Black, 6.6% Hispanic/Latino, 4.0% Asian, and 0.3% Indigenous. Compared with patients of White race, the odds of robotic surgery were lower for Black (OR 0.89, 95% CI 0.86–0.93) and Indigenous patients (OR 0.72, 95% CI 0.59–0.89), but higher for Hispanic/Latino (OR 1.12, 95% CI 1.08–1.17) and Asian patients (OR 1.27, 95% CI 1.21–1.34). Indigenous patients had higher odds of readmission (OR 1.41, 95% CI 1.23–1.62), 90‐day mortality (OR 1.31, 95% CI 1.11–1.54), and worse overall survival (HR 1.11, 95% CI 1.05–1.18). Conclusion: Indigenous and Black patients have lower utilization of minimally invasive approaches and worse outcomes in GI cancer care.